This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Frances E. Knock, PhD, MD; Raymond M. Galt, MD; Y.T. Oester, MD, PhD
Chicago

JAMA. 1970;214(1):146.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

In sensitivity tests on hundreds of human cancers, selected sulfhydryl (SH) inhibitors have shown greater effect against tumors than against normal tissues. Clinically, SH inhibitors have caused the regression of a variety of human carcinomas, sarcomas, and lymphomas without injury to wound healing and with minimal injury to hematologic status and even improvement in some patients. The drug regimens are started within 24 to 48 hours of major cancer surgery, such as palliative bowel resection or pelvic exenteration. In two series totalling over 100 patients, the majority of patients whose tumors could be measured objectively received objective benefit from chemotherapy with the SH inhibitor oxophenarsine plus adjuncts, alone or in combination with other anticancer drugs which were picked in accord with sensitivity tests on each patient's own cancer.¹

From the work of Di Paolo² and Kondo³ the sensitivity tests are now known to be . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?